Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05282550 · ClinicalTrials.gov registry record · Phase 2
Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone
A Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05282550: Recruiting Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment, sponsored by Johns Hopkins University.
NCT05282550 is a Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 100 participants, below the 176-participant average among 56 other Sleep Disturbance trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05282550, a Phase 2 study of Sleep Disturbance and AMCI - Amnestic Mild Cognitive Impairment, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).
Primary Outcome
Comparison of means of total sleep duration from baseline measured in minutes between trazodone and placebo arm.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Trazodone
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT05282550 shows while recruiting
NCT05282550 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 176-participant average among 56 other Sleep Disturbance trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Sleep Disturbance appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05282550 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05282550 about?
NCT05282550 is a clinical study titled "Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone". To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).
What is the current status of trial NCT05282550?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-02-02. Estimated completion is 2028-06-30.
What conditions does trial NCT05282550 study?
This clinical trial studies the following conditions: Sleep Disturbance, AMCI - Amnestic Mild Cognitive Impairment.
What interventions are being tested in trial NCT05282550?
The interventions under investigation include: Placebo (DRUG), Trazodone (DRUG).
Who is sponsoring clinical trial NCT05282550?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05282550 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sleep Disturbance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05282550's enrollment target sits among peer trials
100 23rd of 56 higher than 30 of 56 other Sleep Disturbance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sleep Disturbance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
RECRUITING · Phase 2
-
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
ACTIVE NOT RECRUITING · Phase 2
-
RECOVER-SLEEP: Platform Protocol
COMPLETED · Phase 2
-
Clinical Benefits of a Novel Sleep-focused Mind-body Program on Gulf War Illness (GWI) Symptoms
COMPLETED · Phase 2
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
-
Sleep and Central Auditory Processing Disorder in Autism Spectrum Disorder
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI